Newsroom
Category
December 7, 2012
Studies of how to overcome drug resistance in deadly central nervous system tumors called glioblastomas will propel forward thanks to $755,718 from the Cancer Prevention & Research Institute of Texas.
December 7, 2012
The ability of rapamycin-related drugs to potentially slow the aging process — suggested in animal experiments at The University of Texas Health Science Center San Antonio — has led to establishment of a new San Antonio biotech company, Rapamycin Holdings Inc., which is licensing exclusive rights to intellectual property central to several aspects of the rapamycin-related drugs.
December 6, 2012
A tool called microarray testing can help doctors to more often pinpoint the potential genetic reason for a stillbirth, so that more couples can learn what happened to their babies, a study of 500 stillbirths in San Antonio and four other cities showed.
December 6, 2012
Doctoral students, nursing students, and officials of the UT Health Science Center San Antonio and the Baptist Health Foundation of San Antonio are celebrating $1.5 million in gifts from the estate of Laura A. Adler in memory of her husband, Harry F. Adler, M.D., Ph.D.
December 5, 2012
etails concerning the licensing of rapamycin-related intellectual property developed at the UT Health Science Center San Antonio to an emerging spin-out company, Rapamycin Holdings Inc. Rapamycin, a drug federally approved to suppress organ rejection, continues to be studied for its potential to slow the aging process and its efficacy in treating age-related diseases.
December 4, 2012
The 35th annual CTRC-AACR San Antonio Breast Cancer Symposium, where close to 7,500 researchers, clinicians and advocates from around the world are gathering to present and hear about the latest research, trends and topics of discussion in breast cancer, including drug trials and treatment methods.